RARA CRAFT DATABASE for FDA Medical Devices
510(k)K223752

FDA DEVICE FACTS

Black Non Sterile Powder Free Nitrile Examination Gloves, Tested for Use with Chemotherapy Drugs, with Chloroquine, Cyclosporin A, Retrovir, Gastric Acid and Fentanyl

Central Medicare Sdn Bhd

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

DECISION DATEJuly 24, 2023PRODUCT CODELZA

Indications for use

Black Non Sterile Powder Free Nitrile Examination Gloves, Tested for Use with Chemotherapy Drugs, with Chloroquine, Cyclosporin A, Retrovir, Gastric Acid and Fentany] is a disposable device intended for medical purposes that is worn on the examiner's hand to prevent contamination between patient and examiner. In addition, these gloves were tested for use with chemotherapy drugs, with chloroquine, cyclosporin A, retrovir, gastric acid and fentanyl citrate in accordance with ASTM D6978-05(2019). Tested chemotherapy drugs and average breakthrough detection time (minutes) are as follows: Chemotherapy Drug Concentration Breakthrough Detection Time in Minutes Bleomycin Sulfate 15.0 mg/ml > 240 mins Busulfan 6.0 mg/ml > 240 mins Carboplatin 10.0 mg/ml > 240 mins Carmustine (BCNU) 3.3 mg/ml 13.2 mins Cisplatin 1.0 mg/ml > 240 mins Cyclophosphamide (Cytoxan) 20.0 mg/ml > 240 mins Cytarabine (Cytosine) 100.0 mg/ml > 240 mins Dacarbazine 10.0 mg/ml > 240 mins Daunorubicin HCI 5.0 mg/ml > 240 mins Docetaxel 10.0 mg/ml > 240 mins Doxorubicin HCl 2.0 mg/ml > 240 mins Epirubicin HCI (Ellence) 2.0 mg/ml > 240 mins Etoposide (Toposar) 20.0 mg/ml > 240 mins Fludarabine 25.0 mg/ml > 240 mins Fluorouracil 50.0 mg/ml > 240 mins Gemcitabine (Gemzar) 38.0 mg/ml > 240 mins Idarubicin HCl 1.0 mg/ml > 240 mins Ifosfamide 50.0 mg/ml > 240 mins Irinotecan 20.0 mg/ml > 240 mins Mechlorethamine HCl 1.0 mg/ml > 240 mins Melphalan 5.0 mg/ml > 240 mins Methotrexate 25.0 mg/ml > 240 mins Mitomycin C 0.5 mg/ml > 240 mins Mitoxantrone HCl 2.0 mg/ml > 240 mins Oxaliplatin 5.0 mg/ml > 240 mins Paclitaxel 6.0 mg/ml > 240 mins Paraplatin 10.0 mg/ml > 240 mins Rituximab 10.0 mg/ml > 240 mins Thiotepa 10.0 mg/ml 34.7 mins Topotecan HCl 1.0 mg/ml > 240 mins Trisenox (Arsenic Trioxide) 1.0 mg/ml > 240 mins Velcade (Bortezomib) 1.0 mg/ml > 240 mins Vincristine Sulfate 1.0 mg/ml > 240 mins Tested non-chemotherapy drugs and average breakthrough detection time (minutes) are as follows: Non-Chemotherapy Drug Concentration Breakthrough Detection Time in Minutes Chloroquine 50.0 mg/ml > 240 mins Cyclosporin A 100.0 mg/ml > 240 mins Retrovir 10.0 mg/ml > 240 mins Fentanyl Permeation - Under the testing conditions of ASTM D6978-05(2019), Fentanyl Citrate Injection (100mcg/2mL) was found to have no breakthrough detected up to 240 minutes. Gastric Acid Permeation - Under the testing conditions of ASTM D6978-05(2019), was found to have no breakthrough detected up to 240 minutes. CAUTION: Testing showed an average breakthrough time of 13.2 minutes with Carmustine and 34.7 minutes with Thiotepa. WARNING: Do not use with Carmustine and Thiotepa.

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: August 18, 2026